Casma Therapeutics to Present at the Gordon Research Conference on Autophagy in Stress, Development, and Disease

February 28, 2024

CAMBRIDGE, Mass., February 28, 2024Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer and Dan Baird Ph.D., Vice President, Molecular Discovery will participate in the Gordon Research Conference on Autophagy in Stress, Development, and Disease in Lucca, Italy. Dr. Murphy will be leading a session entitled “Aging and Inflammation” on March 13, 2024. Dr. Baird will participate in a panel on March 10, 2024, and will be presenting a poster entitled “Targeting the FIP200 Initiation Complex to Direct Selective Autophagy and Activate Bulk Autophagy” on March 11, 2024.


About Casma Therapeutics
Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more complex disease targets, such as organelles, protein aggregates, and large signaling complexes, and directs these targets to the lysosome for elimination. Through selective degradation of disease targets, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders.


Contact for Investors and Media

Courteney Backstrom
Casma Therapeutics, Inc.


Back to news & media

Keep reading: